Drug intelligence / Profile preview

NPH insulin + insulin lispro

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

The combination of NPH insulin and insulin lispro is a treatment regimen used for diabetes management that pairs an intermediate-acting insulin (NPH) with a rapid-acting insulin analog (insulin lispro). ## Description NPH insulin + insulin lispro is a combination therapy used in the treatment of both type 1 and type 2 diabetes mellitus. This regimen combines NPH (Neutral Protamine Hagedorn) insulin, an intermediate-acting insulin, with insulin lispro (brand name Humalog), a rapid-acting insulin analog. The combination provides both immediate and extended glucose control. Insulin lispro works rapidly, with onset within 15-30 minutes and peak action within 30-90 minutes, making it ideal for mealtime coverage. NPH insulin has a slower onset (2-4 hours) and longer duration (12-18 hours), providing basal insulin coverage between meals and overnight[1][2]. Studies have shown that using insulin lispro with NPH insulin in a twice-daily regimen allows injection closer to mealtime and improves post-prandial glycemic control without increasing hypoglycemia risk[1]. The combination has demonstrated better overall blood glucose control in type 1 diabetic patients compared to regular human insulin with NPH[2]. ## Administration When mixing these insulins: - Insulin lispro should be drawn into the syringe first, followed by NPH insulin[3][6] - Injection should occur immediately after mixing[3][6] - The combination is typically administered in a twice-daily regimen[1] This combination is not pre-mixed commercially but is prepared by the patient or healthcare provider at the time of administration. The mixing order is important to prevent potential compatibility issues. ## Benefits The primary advantages of this combination include: - Improved postprandial glucose control compared to regular insulin + NPH[1][2] - Ability to inject closer to mealtime due to insulin lispro's rapid onset[1] - Better overall glycemic control as measured by HbA1c levels[2] - Similar or reduced risk of hypoglycemia compared to regular insulin + NPH[1][2] - Greater patient acceptance and treatment satisfaction[2] ## Considerations For optimal use of this combination: - The timing between meals should be considered, as insulin lispro's shorter duration may lead to hyperglycemia if meals are spaced too far apart[8] - Additional doses of NPH may be needed at lunch to meet basal insulin requirements between meals if dinner is eaten late[8] - Patients with unpredictable eating habits may benefit from insulin lispro's flexibility, as it can be timed with meals[8] This combination represents an important treatment option for diabetes management, offering improved glycemic control with the convenience of mealtime dosing flexibility.

Brand names
Humalog Mix 75/25
Other names
NPH insulin + lispro
02

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on NPH insulin + insulin lispro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPH insulin + insulin lispro.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call